Table 2.
Clinical data of patients developing HBV reactivation after systemic anticancer treatment. 3TC, lamivudine; ALT, alanine aminotransferase; ASP8273, an EGFR TKI; ETV, entecavir; LdT, telbivudine; TAF, tenofovir alafenamide; TKI, tyrosine kinase inhibitor. # The treatment duration in patients receiving first-line TKI only was counted since the initiation of TKI, while those receiving chemotherapy with previous TKI treatment was counted since the initiation of chemotherapy. $ HBV reactivation without HBV-related hepatitis. @ HBV prophylaxis before chemotherapy.
| Patient No. | Baseline Characteristics | Antineoplastic Treatment | HBV Reactivation | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Age/Sex | HBsAg | ALT (U/L) | Medication Courses | Duration # (Month) |
Peak ALT (U/L) |
HBV Viral Load (IU/mL) | Rescue NUC Therapy | Clinical Outcome | |
| 1 | 58/F | Positive | 48 | TKI then chemotherapy | 5.1 | 277 | >1.70 × 108 | ETV | liver failure |
| 2 | 67/F | Positive | 51 | TKI then chemotherapy | 0.9 | 169 | 1.05 × 105 | ETV | ALT decreased |
| 3 | 60/F | Positive | 15 | TKI then chemotherapy | 15.6 | 1074 | >1.70 × 108 | ETV | liver failure |
| 4 | 45/F | Positive | 63 | Erlotinib | 25.0 | 19 $ | 2.25 × 104 | ETV @ | |
| 5 | 62/F | Positive | 30 | Gefitinib | 1.9 | 140 | 7.03 × 103 | ETV | ALT decreased |
| 6 | 48/F | Positive | 20 | Gefitinib then osimertinib | 19.6 | 161 | 8.00 × 104 | ETV | ALT decreased |
| 7 | 50/M | Positive | 27 | Erlotinib then osimertinib | 24.4 | 16 $ | >1.70 × 108 | TAF @ | |
| 8 | 57/M | Positive | 20 | Gefitinib | 9.3 | 65 $ | 6.44 × 107 | ETV | ALT decreased |
| 9 | 70/M | Positive | 19 | Gefitinib | 1.6 | 125 | 2.82 × 105 | ETV | ALT decreased |
| 10 | 57/F | Positive | 30 | Gefitinib | 14.5 | 31 $ | 4.51 × 104 | ETV @ | |
| 11 | 70/M | Positive | 21 | Erlotinib | 4.0 | 355 | 1.03 × 105 | LdT | ALT decreased |
| 12 | 49/F | Positive | 12 | Erlotinib | 13.3 | 52 $ | 5.51 × 104 | nil | |
| 13 | 66/F | Positive | 20 | Afatinib | 0.5 | 1293 | >1.70 × 108 | ETV | ALT decreased |
| 14 | 67/F | Positive | 32 | ASP8273 then gefitinib | 5.1 | 1227 | 1.11 × 105 | ETV | ALT decreased |
| 15 | 67/M | Positive | 40 | Afatinib | 31.9 | 58 $ | 2.47 × 106 | nil | |
| 16 | 60/M | Positive | 104 | Erlotinib | 2.5 | 191 | 5.93 × 106 | ETV | ALT decreased |
| 17 | 59/F | Positive | 21 | Erlotinib then osimertinib | 13.1 | 552 | 7.93 × 106 | ETV | ALT decreased |
| 18 | 59/M | Positive | 44 | Erlotinib | 8.4 | 26 $ | 3.87 × 106 | ETV @ | |
| 19 | 67/M | Negative | 16 | Afatinib then osimertinib | 25.9 | 529 | 2.45 × 105 | ETV + 3TC | ALT decreased |